ARTICLE | Clinical News
Phenoptin: Phase III data
March 20, 2006 8:00 AM UTC
In a 6-week, double-blind, placebo-controlled, international Phase III trial in 87 evaluable patients with elevated blood Phe levels, Phenoptin met all primary and secondary endpoints. Patients treate...